01/06/06 6682-63358-09 471258 CGL01/0125US1;A00066-00517.0010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Liao et al.

Application No. 10/502,040

Filed: July 19, 2004

Confirmation No. 7115

ALANINE 2, 3-AMINOMUTASE

Examiner: Elizabeth Slobodyansky

Art Unit: 1652

Attorney Reference No. 6682-63358-09

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed January 6.

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several Englishlanguage documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Sheree Lynn Rybak, PKI Registration No. 47,913

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

cc: Docketing

PE	
INFORMATION	DISCLOSURE STATEMENT
INFORMATION &	APPLICANT

Attorney Docket Number	6682-63358-09
Application Number	10/502,040
Filing Date	July 19, 2004
First Named Inventor	Liao
Art Unit	1652
Examiner Name	Elizabeth Slobodyansky

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,136,576	10/24/2000	Diaz-Torres et al.
		2003/0113882 A1	6/19/20003	Frey et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/21771 A2	03/29/2001	Omnigene Bioproducts
•				·	

L	·			
Examiner's Initials*	Cite No. (optional)	CHERRIDIC CONTRACTOR OF CONTRA		
		Begley et al., "The Biosynthesis of Coenzyme A in Bacteria," Vitam. Horm. 61:157-171 (2001).		
		Cronan, "β-Alanine Synthesis in Escherichia coli," J. Bacteriol. 141:1291-1297 (1980).		

 DATE CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.